Investors maintained a strong pace of deal-making in the Indian pharmaceutical and healthcare sector during Q3 2024. Key players drove growth through strategic transactions in pharma, biotech, and healthcare services. Our latest Dealtracker report analyses the quarter's trends, notable deals, and emerging sectors that are reshaping the industry.
Key insights from the Pharma and Healthcare Dealtracker Q3 2024:
- Rise in domestic deals: M&A activity saw significant growth, achieving record-high quarterly deal volumes and the highest deal values since Q4 2022, indicating a highly active market for consolidation. Domestic deals were at the forefront, reaching an all-time high value of USD 1.9 billion and the highest deal volumes since Q2 2021, reflecting a robust domestic market.
- Shift to low-value PE investments: The quarterly values dropped by nearly 91% over the previous quarter due to the absence of big-ticket transactions. The PE space was largely driven by smaller deals (≤ USD 5 million), which accounted for 76% of the total volumes.
- Robust capital market activity: The quarter witnessed two of the biggest IPOs in the sector in 2024. Additionally, QIP activity experienced a significant boost, with volumes and values increasing by 50% and 98%, respectively witnessing 3 fund raise worth USD 214 million, compared to the previous quarter.
